Future studies should further explore the potential of small-molecule inhibitors of HSPA5/6 for the treatment of CTCL in vivo and primary CTCL patient cells. This evidence concerns the gene HSPA5 and primary cutaneous T-cell non-Hodgkin lymphoma.